Total Payments
$118,851
2024 Payments
$44,967
Companies
13
Transactions
93
Medicare Patients
1,071
Medicare Billing
$304,388
Payment Breakdown by Category
Other$55,944 (47.1%)
Consulting$52,044 (43.8%)
Travel$7,888 (6.6%)
Food & Beverage$2,942 (2.5%)
Gifts$33.10 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $52,044 | 18 | 43.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $39,606 | 13 | 33.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $16,338 | 9 | 13.7% |
| Travel and Lodging | $7,888 | 23 | 6.6% |
| Food and Beverage | $2,942 | 29 | 2.5% |
| Gift | $33.10 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eisai Inc. | $24,324 | 15 | $0 (2023) |
| Aveo Pharmaceuticals, Inc. | $18,828 | 14 | $0 (2024) |
| PFIZER INC. | $14,902 | 13 | $0 (2024) |
| Janssen Biotech, Inc. | $14,663 | 20 | $0 (2024) |
| Myovant Sciences Inc. | $12,747 | 4 | $0 (2022) |
| Exelixis Inc. | $10,737 | 11 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $7,770 | 4 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $5,880 | 3 | $0 (2024) |
| Amgen Inc. | $3,894 | 1 | $0 (2021) |
| RefleXion Medical, Inc. | $2,471 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $44,967 | 45 | Aveo Pharmaceuticals, Inc. ($17,013) |
| 2023 | $41,677 | 33 | Eisai Inc. ($15,048) |
| 2022 | $25,120 | 12 | Myovant Sciences Inc. ($12,747) |
| 2021 | $7,087 | 3 | Amgen Inc. ($3,894) |
All Payment Transactions
93 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $140.00 | General |
| Category: Oncology | ||||||
| 11/26/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,100.00 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,513.00 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | Cash or cash equivalent | $205.88 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | Cash or cash equivalent | $48.05 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | Cash or cash equivalent | $18.68 | General |
| Category: Oncology | ||||||
| 11/01/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $550.00 | General |
| Category: Oncology | ||||||
| 10/30/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $5,445.00 | General |
| Category: Oncology | ||||||
| 10/28/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,125.00 | General |
| Category: Oncology | ||||||
| 10/25/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | Cash or cash equivalent | $127.79 | General |
| Category: Oncology | ||||||
| 10/25/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | Cash or cash equivalent | $20.04 | General |
| Category: Oncology | ||||||
| 10/19/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 10/17/2024 | US Oncology Corporate, Inc. | — | Travel and Lodging | Cash or cash equivalent | $673.85 | General |
| 10/17/2024 | US Oncology Corporate, Inc. | — | Food and Beverage | Cash or cash equivalent | $402.00 | General |
| 10/17/2024 | US Oncology Corporate, Inc. | — | Travel and Lodging | Cash or cash equivalent | $371.66 | General |
| 10/17/2024 | US Oncology Corporate, Inc. | — | Gift | Cash or cash equivalent | $33.10 | General |
| 10/15/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | In-kind items and services | $206.11 | General |
| Category: Oncology | ||||||
| 10/14/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,125.00 | General |
| Category: Oncology | ||||||
| 10/09/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $302.50 | General |
| Category: Oncology | ||||||
| 10/09/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Travel and Lodging | In-kind items and services | $272.96 | General |
| Category: Oncology | ||||||
| 10/09/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $139.93 | General |
| Category: Oncology | ||||||
| 10/06/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | In-kind items and services | $237.05 | General |
| Category: Oncology | ||||||
| 10/05/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 09/11/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,513.00 | General |
| Category: Oncology | ||||||
| 09/06/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Consulting Fee | Cash or cash equivalent | $1,387.50 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 354 | 979 | $258,755 | $103,819 |
| 2022 | 5 | 306 | 866 | $213,344 | $94,064 |
| 2021 | 7 | 271 | 720 | $157,177 | $72,306 |
| 2020 | 5 | 140 | 367 | $74,630 | $34,200 |
Total Patients
1,071
Total Services
2,932
Medicare Billing
$304,388
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 44 | 282 | $108,570 | $36,749 | 33.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 137 | 385 | $78,253 | $34,416 | 44.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 75 | 165 | $46,722 | $21,513 | 46.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 54 | 54 | $18,886 | $8,798 | 46.6% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 44 | 93 | $6,324 | $2,343 | 37.0% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2022 | 39 | 270 | $103,878 | $36,861 | 35.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 122 | 353 | $61,941 | $33,120 | 53.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 67 | 114 | $27,858 | $15,519 | 55.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 39 | 39 | $13,059 | $6,317 | 48.4% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 39 | 90 | $6,608 | $2,247 | 34.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 85 | 346 | $59,166 | $33,209 | 56.1% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2021 | 24 | 156 | $59,988 | $20,336 | 33.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 51 | 51 | $16,881 | $8,376 | 49.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 42 | 50 | $11,600 | $6,953 | 59.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 28 | 44 | $5,104 | $2,104 | 41.2% |
| 96402 | Hormonal anti-neoplastic chemotherapy administration beneath the skin or into muscle | Office | 2021 | 24 | 51 | $4,284 | $1,262 | 29.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 17 | 22 | $154.00 | $66.00 | 42.9% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2020 | 11 | 76 | $28,396 | $12,964 | 45.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 47 | 141 | $24,104 | $11,322 | 47.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 45 | 100 | $11,508 | $5,315 | 46.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 26 | 26 | $8,606 | $4,068 | 47.3% |
| 96402 | Hormonal anti-neoplastic chemotherapy administration beneath the skin or into muscle | Office | 2020 | 11 | 24 | $2,016 | $530.52 | 26.3% |
About David Gill
David Gill is a Medical Oncology healthcare provider based in Murray, Utah. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/06/2014. The National Provider Identifier (NPI) number assigned to this provider is 1649698697.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, David Gill has received a total of $118,851 in payments from pharmaceutical and medical device companies, with $44,967 received in 2024. These payments were reported across 93 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($52,044).
As a Medicare-enrolled provider, Gill has provided services to 1,071 Medicare beneficiaries, totaling 2,932 services with total Medicare billing of $304,388. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Murray, UT
- Active Since 04/06/2014
- Last Updated 06/16/2019
- Taxonomy Code 207RX0202X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1649698697
Products in Payments
- Lenvima (Drug) $24,324
- FOTIVDA (Drug) $18,828
- TALZENNA (Drug) $13,652
- ERLEADA (Drug) $13,300
- ORGOVYX (Drug) $12,747
- CABOMETYX (Drug) $10,641
- LYNPARZA (Drug) $6,383
- REFLEXION MEDICAL RADIOTHERAPY SYSTEM (Device) $2,471
- ENHERTU (Biological) $1,388
- INLYTA (Drug) $1,250
- ILLUCCIX (Drug) $336.12
- Cabometyx (Drug) $96.56
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.